Skip to main content
Figure 3 | BMC Cancer

Figure 3

From: The combination of ANT2 shRNA and hNIS radioiodine gene therapy increases CTL cytotoxic activity through the phenotypic modulation of cancer cells: combination treatment with ANT2 shRNA and I-131

Figure 3

The modulation of phenotypic markers in CT26/NF cells treated with ANT shRNA and hNIS radioiodine combination therapy. (A) and (C) Representative flow cytometry data for MHC class I and Fas are shown. (B) and (D) The Y axis indicates the relative increase in MHC class I and Fas expression levels in cancer cells. A total of 10,000 cells were analyzed, and the relative% depicts the increased percentage of surface marker gene expression of treated cells compared with control. The data shown are the mean of triplicate experiments; the bars represent the mean ± SD.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us